#None #partnerships #Therapeutic Antibodies #Adimab

Exceptional Growth in Collaborations and Programs for Adimab

Adimab, LLC, a frontrunner in the discovery and engineering of fully human monoclonal and multispecific antibodies, announced an impressive year marked by a total of 23 partnership agreements established in 2025. This milestone reflects the company's commitment to advancing therapeutic innovations in collaboration with many prominent players in the pharmaceutical industry.

The collaborations formed in the past year included key partnerships with Central Therapeutics, Enara Bio, Onco3R, Roivant, Variant Bio, and Triptych. Furthermore, Adimab expanded existing collaborations with notable companies such as Alnylam, 3T Biosciences, Compugen, Cullinan Therapeutics, Lilly, Regeneron, RedRidge, and Therini. These expansions are a testament to Adimab’s ability to provide innovative solutions that meet the diverse needs of its partners.

In total, Adimab's initiatives in 2025 led to the commencement of 75 new therapeutic programs. This brings the overall count of royalty-bearing programs to more than 650 since the company's inception. The expansion of these programs indicates a healthy growth trajectory and ongoing interest from both new and existing partners to leverage Adimab’s pioneering technology.

Guy Van Meter, the Chief Business Officer of Adimab, emphasized how the company's unique offerings distinguish it in a competitive landscape. He stated, "We continue to distinguish ourselves by providing solutions for our partners that others cannot. Our offerings in the multispecific space, from plug-and-play T cell engagers to heterodimerization solutions, make that clear."

Under the leadership of CEO Philip T. Chase, Adimab adopts a reinvestment strategy focused on augmenting its capabilities and technology. The emphasis on maintaining cutting-edge technology ensures that partners consistently seek Adimab for their therapeutic needs.

Advanced Technologies at Adimab

Adimab's diverse range of technologies enhances its antibody discovery and engineering processes significantly.

Antibody Discovery

Adimab employs a proprietary yeast-based technology for the discovery of therapeutic antibodies in both IgG and VHH formats. This platform utilizes both synthetic and in vivo source diversity to produce antibodies with remarkable specificity for various applications, including monoclonal and multispecific formats, CAR-T therapies, and ADCs.

Engineering Capabilities

The company boasts refined engineering capabilities developed over numerous antibody optimization projects. The process begins with selected lead antibodies provided by partners, aiming to enhance their potency, specificity, and developability. This flexibility allows for engineered antibodies to be sourced from various origins to fix suboptimal properties.

Expertise in Multispecific Development

Adimab excels in the bispecific and multispecific domains, offering proprietary solutions for Fc and Fab heterodimerization, generating versatile product designs with favorable development properties. Over 20 partners utilize these mutation sets to advance their research and development efforts.

T Cell Engager Programs

Adimab provides an extensive suite of characterized CD3 and CD28 antibodies for creating bi- and multispecific T cell engagers. This program is non-exclusively partnered with over 25 entities, showcasing the versatility and demand for Adimab's offerings.

Addressing Complex Targets

For notoriously difficult targets like membrane-obligate proteins, Adimab has developed discovery workflows that efficiently operate in the proteins' native states, leading to effective identification of antibodies that maintain their functionality.

Conclusion

In summary, Adimab's progress in 2025 underscores its strong position in the therapeutic antibody field. With an ongoing commitment to innovation and partnership, the company is poised to continue its leadership role and deliver substantial advancements in drug development. By focusing solely on its partners and abstaining from developing its internal product pipeline, Adimab uniquely positions itself to contribute effectively to the broader biopharmaceutical landscape.